Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Diabet Med ; 41(2): e15262, 2024 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-38017692

RESUMO

AIMS: Bespoke glycaemic control strategies following antenatal corticosteroids for women with diabetes in pregnancy (DIP) may mitigate hyperglycaemia. This study aims to identify predictive factors for the glycaemic response to betamethasone in a large cohort of women with DIP. METHODS: Evaluation of a prospective cohort study of 347 consecutive DIP pregnancies receiving two doses of 11.4 mg betamethasone 24 h apart between 2017 and 2021 and treated with the Pregnancy-IVI intravenous insulin protocol. Regression modelling identified factors associated with maternal glycaemic time-in-range (TIR) and maternal insulin requirements following betamethasone. Factors associated with neonatal hypoglycaemia (glucose <2.6 mmol/L) in infants born within 48 h of betamethasone administration (n = 144) were investigated. RESULTS: The mean maternal age was 31.9 ± 5.8 years, with gestational age at betamethasone of 33.5 ± 3.4 weeks. Gestational diabetes was present in 81% (12% type 1; 7% type 2). Pre-admission subcutaneous insulin was prescribed for 63%. On-infusion maternal glucose TIR (4.0-7.8 mmol/L) was 83% [IQR 77%-90%] and mean on-IVI glucose was 6.6 ± 0.5 mmol/L. Maternal hypoglycaemia (<3.8 mmol/L) was uncommon (0.47 h/100 on-IVI woman hours). Maternal glucose TIR was negatively associated with indicators of insulin resistance (type 2 diabetes, polycystic ovary syndrome), late-pregnancy complications (pre-eclampsia, chorioamnionitis) and the 1-h OGTT result. Intravenous insulin requirements were associated with type of diabetes, pre-eclampsia and intrauterine infection, the 1-h OGTT result and the timing of betamethasone administration. Neonatal hypoglycaemia was associated with pre-existing diabetes but not with measures of glycaemic control. CONCLUSION: An intravenous infusion protocol effectively controls maternal glucose after betamethasone. A risk-factor-based approach may allow individualisation of therapy.


Assuntos
Diabetes Mellitus Tipo 2 , Diabetes Gestacional , Doenças Fetais , Hiperglicemia , Hipoglicemia , Pré-Eclâmpsia , Gravidez em Diabéticas , Recém-Nascido , Gravidez , Feminino , Humanos , Adulto , Lactente , Diabetes Gestacional/tratamento farmacológico , Diabetes Gestacional/epidemiologia , Diabetes Mellitus Tipo 2/tratamento farmacológico , Betametasona/uso terapêutico , Hiperglicemia/prevenção & controle , Estudos Prospectivos , Hipoglicemia/induzido quimicamente , Hipoglicemia/epidemiologia , Hipoglicemia/prevenção & controle , Gravidez em Diabéticas/tratamento farmacológico , Parto , Insulina/efeitos adversos , Glucose
2.
Drug Res (Stuttg) ; 73(9): 491-505, 2023 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-37890514

RESUMO

Eukaryotic organisms contain an enzyme family called poly (ADP-ribose) polymerases (PARPs), which is responsible for the poly (ADP-ribosylation) of DNA-binding proteins. PARPs are members of the cell signaling enzyme class. PARP-1, the most common isoform of the PARP family, is responsible for more than 90% of the tasks carried out by the PARP family as a whole. A superfamily consisting of 18 PARPs has been found. In order to synthesize polymers of ADP-ribose (PAR) and nicotinamide, the DNA damage nick monitor PARP-1 requires NAD+ as a substrate. The capability of PARP-1 activation to boost the transcription of proinflammatory genes, its ability to deplete cellular energy pools, which leads to cell malfunction and necrosis, and its involvement as a component in the process of DNA repair are the three consequences of PARP-1 activation that are of particular significance in the process of developing new drugs. As a result, the pharmacological reduction of PARP-1 may result in an increase in the cytotoxicity toward cancer cells.


Assuntos
Inibidores de Poli(ADP-Ribose) Polimerases , Ribose , Humanos , Inibidores de Poli(ADP-Ribose) Polimerases/farmacologia , Inibidores de Poli(ADP-Ribose) Polimerases/uso terapêutico , Poli(ADP-Ribose) Polimerases/química , Poli(ADP-Ribose) Polimerases/metabolismo , Necrose , Transdução de Sinais
4.
J Family Med Prim Care ; 9(3): 1744-1748, 2020 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-32509683

RESUMO

Odontogenic myxoma is a benign, rare neoplasm of mesenchymal origin comprising of 3%-6% of all odontogenic tumors. Odontogenic myxoma occurs more commonly in the second and third decade and is more commonly seen in mandible compared with maxilla but behaves more aggressively in maxilla as it spreads through the maxillary antrum. It is usually associated with a painless swelling without any symptoms. The radiographic features are similar to other odontogenic tumors, and hence, it leads to diagnostic dilemma. Therefore, thorough knowledge regarding clinical, radiographical, and histopathological features are important to arrive at a proper treatment protocol as it shows a high recurrence rate. The aim of this paper was to present a rare case of 21-year-old male with a chief complaint of swelling in the left maxilla that infiltrated the maxillary sinus in a very short duration.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...